<turbo-stream action="append" target="news"><template>  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260603064216/en/Ryder-CEO-John-Diez-to-Address-Wells-Fargo-16th-Industrials-Materials-Conference/">Ryder CEO John Diez to Address Wells Fargo 16th Industrials &amp; Materials Conference</a>
    </div>

      <div class="me-0 me-md-5">
        MIAMI--(BUSINESS WIRE)-- #RyderEverbetter--Ryder System, Inc. (NYSE: R) CEO John Diez to address the Wells Fargo 16th Industrials &amp; Materials Conference. Who:  Ryder System, Inc. CEO John Diez What: Wells Fargo 16th Industrials &amp; Materials Conference When:  Wednesday, June 10, 2026 Time: 11:00 a.m. Central Time Webcast: To access the live webcast, visit Ryder - Wells Fargo 16th Industrials &amp; Ma...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/sunshine-biopharma-announces-canadian-approval-for-rivaroxaban-a-gene-1172103">Sunshine Biopharma Announces Canadian Approval for Rivaroxaban, a Generic Form of Xarelto(R)</a>
    </div>

      <div class="me-0 me-md-5">
        FORT LAUDERDALE, FL / ACCESS Newswire / June 1, 2026 / Sunshine Biopharma Inc. (NASDAQ:SBFM) (the &quot;Company&quot;), a leading pharmaceutical company specializing in generic and specialty prescription medications, is pleased to announce the approval of its generic Rivaroxaban tablets of 2.5mg, 10mg, 15mg and 20mg for the Canadian market. Rivaroxaban is the generic equivalent of the brand name anticoag...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/metals-and-mining/core-critical-approved-for-listing-on-otcqbr-venture-market-1172001">Core Critical Approved for Listing on OTCQB(R) Venture Market</a>
    </div>

      <div class="me-0 me-md-5">
        VANCOUVER, BC / ACCESS Newswire / May 29, 2026 / Core Critical Metals Corp. (&quot;CCMC&quot; or the &quot;Company&quot;) (TSXV:CCMC)(OTCQB:CCMCF) (WKN: A41G8G), a North American mineral acquisition and exploration company, is pleased to announce that its common shares have been approved for listing on the OTCQB® Venture Market, operated by OTC Markets Group Inc. The Company&#39;s shares now trade on the OTCQB under t...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/biotechnology/new-phase-iii-translational-data-show-divitumr-tka-captures-treatment-specific-biolog-1171370">New phase III Translational Data Show DiviTum(R) TKa Captures Treatment-Specific Biological Response in Metastatic Breast Cancer</a>
    </div>

      <div class="me-0 me-md-5">
        UPPSALA, SE / ACCESS Newswire / May 28, 2026 / Biovica International (STO:BIOVIC-B)(STO:BIOVIC.B)(FRA:9II) - Biovica, specializing in blood-based cancer monitoring, today announced new data published in the European Journal of Cancer showing that DiviTumTKa can capture early, treatment-specific biological response in patients with endocrine-resistant HR+/HER2− metastatic breast cancer. The anal...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/business-and-professional-services/totec-resources-approved-for-listing-on-otcqbr-venture-market-1171167">Totec Resources Approved for Listing on OTCQB(R) Venture Market</a>
    </div>

      <div class="me-0 me-md-5">
        VANCOUVER, BC / ACCESS Newswire / May 27, 2026 / Totec Resources Ltd. (&quot;Totec&quot; or the &quot;Company&quot;) (TSXV:TOTC)(OTCQB:TTCRF)(FSE:U0Z0), a leading resource company focused on critical metals and supporting the North American supply chain, is pleased to announce that its common shares have been approved for listing on the OTCQB® Venture Market, operated by OTC Markets Group Inc. The Company&#39;s shares...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Business Wire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 5 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.businesswire.com/news/home/20260527680313/en/Ryder-Earns-VETS-Indexes-3-Star-Employer-Award-for-2026/">Ryder Earns VETS Indexes 3 Star Employer Award for 2026</a>
    </div>

      <div class="me-0 me-md-5">
        MIAMI--(BUSINESS WIRE)--Ryder System, Inc. (NYSE: R) has been recognized as a 3 Star Employer in the 2026 VETS Indexes Employer Awards, underscoring the company&#39;s long‑standing commitment to recruiting, hiring, retaining, developing, and supporting veterans and the military‑connected community. This represents Ryder&#39;s second time receiving this honor, following its 2024 designation as a VETS In...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/biotechnology/bioinvent-reveals-solid-data-with-its-tnfr2-antibody-bi-1808-and-keytrudar-pembrolizu-1169878">BioInvent Reveals Solid Data with its TNFR2 Antibody BI-1808 and KEYTRUDA(R) (pembrolizumab) in Advanced Ovarian Cancer at ASCO</a>
    </div>

      <div class="me-0 me-md-5">
        BioInvent International (STO:BINV) 24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by three the historical single agent activity of 8% in KEYNOTE-100 (2019) 56% disease control rate (DCR) in the combination arm, including multiple durable responses extending beyond 10 months with p...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

  <div class="row mb-4 py-2 news-box">
  <div class="col-12 col-md-8 col-lg-9 order-md-1 order-2">
    <div class="news-box__info-line mb-2">
        <span class="me-2 new badge text-secondary bg-gray-200">
          Neutral
        </span>
        <div class="me-2"><a class="text-gray" data-turbo-frame="_top" href="/aktien/Ryder-System-US7835491082">Ryder System</a></div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">Accesswire</div>
        <div class="me-2 text-gray text-size-10">●</div>
        <div class="me-2 text-gray">vor 6 Monaten</div>
    </div>

    <div class="mb-2">
      <a target="_blank" rel="nofollow" href="https://www.accessnewswire.com/newsroom/en/healthcare-and-pharmaceutical/spago-nanomedical-presents-tumoradr-clinical-data-at-the-internationa-1167686">Spago Nanomedical Presents Tumorad(R) Clinical Data at the International ANZSNM 2026 Conference</a>
    </div>

      <div class="me-0 me-md-5">
        LUND, SE / ACCESS Newswire / May 18, 2026 / Spago Nanomedical AB (publ)(STO:SPAGO.ST)(FRA:7UX.F) today announces that case findings from its ongoing Phase I/IIa clinical study Tumorad-01 have been presented at the 56th Annual Scientific Meeting of the ANZSNM, held in Canberra on 15-17 May 2026. The presentation provided an overview of the study evaluating the radiopharmaceutical drug candidate ...
      </div>
  </div>

  <div class="col-12 col-md-4 col-lg-3 order-md-2 order-1">
  </div>
</div>

</template></turbo-stream><turbo-stream action="replace" target="link"><template><div id="link">
    <a class="btn btn-outline-primary btn--small" data-turbo-stream="" href="/news/Ryder-System-US7835491082/load_more?page=5">
      Mehr Neuigkeiten anzeigen
      <i class="fa fa-arrow-down fa-fw"></i>
</a></div>
</template></turbo-stream>